Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 7/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7351678 | 0.87 | DRD3 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL7351673 | 0.87 | DRD3 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| Pridopidine SCHEMBL166748 | 0.85 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL29664816 | 0.85 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL2370301 | 0.84 | DRD2 (0.97) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL15007479 | 0.84 | DRD2 (0.97) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL17364137 | 0.81 | DRD2 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL29354894 | 0.81 | DRD2 (0.75) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL4819512 | 0.81 | DRD2 (0.78) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL18396165 | 0.81 | DRD2 (0.90) | DRD2SIGMAR1DRD3HTR6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| US-7417043-B2 | Modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-08-26 | — | — | US | disclosed |
| US-20060135531-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1240142-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2005-10-19 | — | — | EP | disclosed |
| US-6903120-B2 | A 4-(phenyl-N- alkyl)-piperidine derivatives for treatment of central nervous system disorders, Parkinson disease, anxiety, dyskinesias, dystonias, Tourette's disease, psychoses, hallucinoses, sleep disorder, autism | A. CARLSSON RESEARCH AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135531-A1 | Modulators of dopamine neurotransmission | SLC6A3, BRS3, CHRNA3 | DRD2 18/4885SIGMAR1 54/4885DRD3 5/4885 |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | DRD2 16/4885SIGMAR1 9/4885DRD3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.